Sec Form 4 Filing - ARCH Venture Fund X, L.P. @ Sana Biotechnology, Inc. - 2021-02-08

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person ARCH Venture Fund X, L.P. 2. Issuer Name and Ticker or Trading Symbol Sana Biotechnology, Inc. [ SANA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 8755 WEST HIGGINS ROAD, SUITE 1025 3. Date of Earliest Transaction (MM/DD/YY) 02/08/2021 (Street) CHICAGO, IL60631 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 02/08/2021 C 10,156,250 A 10,303,750 I See Footnotes ( 2 ) ( 4 ) Common Stock 02/08/2021 C 10,156,250 A 10,301,250 I See Footnotes ( 3 ) ( 4 ) Common Stock 02/08/2021 C 11,718,750 A 11,718,750 I See Footnotes ( 5 ) ( 7 ) Common Stock 02/08/2021 C 11,718,750 A 11,718,750 I See Footnotes ( 6 ) ( 7 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series A-1 Convertible Preferred Stock ( 1 ) 02/08/2021 C 3,687,500 ( 1 ) ( 8 ) Common Stock 3,687,500 $ 0 0 I See Footnotes ( 2 ) ( 4 ) Series A-1 Convertible Preferred Stock ( 1 ) 02/08/2021 C 3,687,500 ( 1 ) ( 8 ) Common Stock 3,687,500 $ 0 0 I See Footnotes ( 3 ) ( 4 ) Series A-2 Convertible Preferred Stock ( 1 ) 02/08/2021 C 5,687,500 ( 1 ) ( 8 ) Common Stock 5,687,500 $ 0 0 I See Footnotes ( 2 ) ( 4 ) Series A-2 Convertible Preferred Stock ( 1 ) 02/08/2021 C 9,375,000 ( 1 ) ( 8 ) Common Stock 9,375,000 $ 0 0 I See Footnotes ( 5 ) ( 7 ) Series A-2 Convertible Preferred Stock ( 1 ) 02/08/2021 C 9,375,000 ( 1 ) ( 8 ) Common Stock 9,375,000 $ 0 0 I See Footnotes ( 6 ) ( 7 ) Series A-2 Convertible Preferred Stock ( 1 ) 02/08/2021 C 5,687,500 ( 1 ) ( 8 ) Common Stock 5,687,500 $ 0 0 I See Footnotes ( 3 ) ( 4 ) Series B Convertible Preferred Stock ( 1 ) 02/08/2021 C 781,250 ( 1 ) ( 8 ) Common Stock 781,250 $ 0 0 I See Footnotes ( 2 ) ( 4 ) Series B Convertible Preferred Stock ( 1 ) 02/08/2021 C 781,250 ( 1 ) ( 8 ) Common Stock 781,250 $ 0 0 I See Footnotes ( 3 ) ( 4 ) Series B Convertible Preferred Stock ( 1 ) 02/08/2021 C 2,343,750 ( 1 ) ( 8 ) Common Stock 2,343,750 $ 0 0 I See Footnotes ( 5 ) ( 7 ) Series B Convertible Preferred Stock ( 1 ) 02/08/2021 C 2,343,750 ( 1 ) ( 8 ) Common Stock 2,343,750 $ 0 0 I See Footnotes ( 6 ) ( 7 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other ARCH Venture Fund X, L.P. 8755 WEST HIGGINS ROAD SUITE 1025 CHICAGO, IL60631 X CRANDELL KEITH 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO, IL60631 X BYBEE CLINTON 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO, IL60631 X Burow Kristina 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO, IL60631 X GILLIS STEVEN 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO, IL60631 X Signatures /s/ Keith Crandell, By: Mark McDonnell, attorney in-fact 02/10/2021 Signature of Reporting Person Date /s/ Clinton Bybee, By: Mark McDonnell, attorney in-fact 02/10/2021 Signature of Reporting Person Date /s/ Kristina Burow, By: Mark McDonnell, attorney in-fact 02/10/2021 Signature of Reporting Person Date /s/ Steven Gillis, By: Mark McDonnell, attorney in-fact 02/10/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The shares of Issuer's Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering. ( 2 )Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX. ( 3 )Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage. ( 4 )ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein. ( 5 )Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X. ( 6 )Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage. ( 7 )ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein. ( 8 )The expiration date is not relevant to the conversion of these securities.

Remarks: Form 2 of 2.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.